KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Receivables (2016 - 2024)

Historic Receivables for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2024 value amounting to $27.1 million.

  • CRISPR Therapeutics AG's Receivables fell 8687.65% to $27.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $27.1 million, marking a year-over-year decrease of 8687.65%. This contributed to the annual value of $27.1 million for FY2024, which is 8687.65% down from last year.
  • As of Q4 2024, CRISPR Therapeutics AG's Receivables stood at $27.1 million, which was down 8687.65% from $206.5 million recorded in Q4 2023.
  • In the past 5 years, CRISPR Therapeutics AG's Receivables ranged from a high of $206.5 million in Q4 2023 and a low of $49000.0 during Q3 2022
  • For the 5-year period, CRISPR Therapeutics AG's Receivables averaged around $29.0 million, with its median value being $10.8 million (2020).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Receivables tumbled by 9970.07% in 2021, and later skyrocketed by 10596060.61% in 2023.
  • CRISPR Therapeutics AG's Receivables (Quarter) stood at $10.8 million in 2020, then decreased by 19.73% to $8.7 million in 2021, then increased by 28.66% to $11.2 million in 2022, then surged by 1743.75% to $206.5 million in 2023, then crashed by 86.88% to $27.1 million in 2024.
  • Its Receivables was $27.1 million in Q4 2024, compared to $206.5 million in Q4 2023 and $70.0 million in Q2 2023.